EGFR-TKI原发性耐药的分子机制及其进展——附2例病例分析
Zhongguo fei ai za zhi = Chinese journal of lung cancer（2019）
Abstract
酪氨酸激酶抑制剂 (tyrosine-kinase inhibitor, TKI) 类药物已经被证实对表皮生长因子受体 (epidermal growth factor receptor, EGFR) 敏感突变的晚期非小细胞肺癌 (non-small cell lung cancer, NSCLC) 患者有很好的疗效, 优于化疗.但仍有部分敏感突变的患者出现原发性耐药.耐药的原因尚不明确, 可能与EGFR基因的敏感突变与耐药突变共存、EGFR通路下游基因突变、MET扩增、BIM缺失多态性等因素相关.本文分享了2例原发性耐药病历并进行了原因分析.
MoreTranslated text
Key words
EGFR-TKI,Lung neoplasms,Primary resistance
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined